Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ga-EC2115 is a folate-based PET radiopharmaceutical developed as an imaging agent for positron emission tomography (PET) to detect activated macrophages in vivo. It targets the folate receptor beta (FRβ), which is expressed on activated macrophages, and is used to monitor inflammation in diseases such as chronic obstructive pulmonary disease (COPD). The compound is administered intravenously and has been evaluated in first-in-human studies for its safety, biodistribution, and ability to image inflammation. Ga-EC2115 was developed by Vanderbilt University Medical Center and synthesized under cGMP procedures. Its primary clinical application has been investigated in COPD patients undergoing bronchoscopy[1][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Ga-EC2115.